Skip to content
Home/Companies/Biotech/eFFECTOR Therapeutics
ET

eFFECTOR Therapeutics

Biotech·US·Exited 2021·Held 8yr

eFFECTOR Therapeutics is a biotech company, headquartered in US.

Entry
2013
Hold
8yr
Exit
2021
Est. EV
–

Who owns eFFECTOR Therapeutics?

eFFECTOR Therapeutics was owned by Abingworth through Abingworth Bioventures VI (2014 vintage) from 2013 to 2021, exited via IPO.

Buyer identity available on Pro.

Hand-verified · updated 2026-05-21

Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
MOIC
–
Exit Year
2021

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Exicure
Active
BiotechUS· 2019
Soleno Therapeutics
Exited 2026
BiotechUS· 2018
to
Tizona Therapeutics
Active
BiotechUS· 2016
Median Technologies
Active
HealthcareFrance· 2015
Avedro
Exited 2019
MedTechUS· 2014
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings